Nymox Pharmaceuticals has existed for 31 years, without bringing any product or drug to market.
NYMX has made many broken promises, delays, and a withdrawal regarding applying for marketing approval in the US and EU.
A competitor met the same primary endpoint that NYMX failed to meet.
Management salaries are excessive, with the CEO receiving over $9M per year at the current share price.
We believe NYMX will crash in 2020 on an equity raise and continued lack of regulatory progress.
Read the full report on Seeking Alpha here.